Duke University

MONTREAL, Sept. 5, 2023 /PRNewswire/ - Find Therapeutics Inc., a biopharmaceutical company focused on the development of innovative therapies for autoimmune diseases, today announced the appointment of Robert L. Glanzman, M.D. FAAN, as Chief Medical Officer. Dr. Glanzman is a board-certified neurologist and Fellow of the American Academy of Neurology with over 20 years of experience in neuroscience-related clinical development. "I am excited to welcome Robert to Find and look forward to leveraging his deep clinical development and operational expertise as we advance our pipeline of novel molecular entities, including our lead program, FTX 101 for chronic optic neuropathy," said Philippe Douville, CEO of Find Therapeutics. "In particular, his clinical development experience in chronic optic neuropathy and his background working for people suffering from multiple sclerosis (MS) make him uniquely qualified for the role. This leadership appointment is timely as we prepare to enter the clinic in 2024." Prior to joining Find Therapeutics, Dr. Glanzman held CMO positions at several biotechnology companies including Clene Nanomedicine, where he led a novel Phase 2 study in MS patients with chronic optic neuropathy as adjunct to standard disease modifying therapies. Dr. Glanzman previously held important leadership roles at Pfizer, Novartis and Roche. While at Novartis he led the US, Phase 3 development of fingolimid (Gilenya®) for patients with relapsing MS, and while at Roche he designed and led the global Phase 3 development program for ocrelizumab (Ocrevus®) for both relapsing and primary progressive forms of MS. Prior to joining industry, Dr. Glanzman held an appointment as Associate Clinical Professor of Neurology at Michigan State University. He has authored numerous peer-reviewed publications. Dr. Glanzman received his doctorate in medicine from Wake Forest University, trained in neurology at the University of Michigan and completed a fellowship in diagnostic nuclear medicine/PET imaging and Duke University. "I am very impressed by Find's promising therapeutic candidates and the Company's differentiated portfolio designed to treat inflammatory autoimmune diseases, especially the program in chronic optic neuropathy," commented Dr. Glanzman. "I look forward to contributing my skills and expertise to advancing Find's clinical programs and ultimately to meeting the unmet needs of people suffering from inflammatory autoimmune diseases." About Find Find Therapeutics is dedicated to the development of next generation therapies to treat inflammatory autoimmune diseases. The company was launched in 2020 with investments from CTI Life Sciences, adMare BioInnovations and Domain Therapeutics and and an exclusive license from Strasbourg University on a technology and related know-how initially developed by Dr. Dominique Bagnard. Visit for more details about Find Therapeutics SOURCE Find Therapeutics Inc.

SAN DIEGO, Sept. 5, 2023 /PRNewswire/ -- Inmagene Biopharmaceuticals ("Inmagene"), a clinical stage biotechnology company developing innovative and differentiated therapies for immunological and inflammatory diseases, today announced the appointment of David Topper as Chief Financial Officer (CFO). David has approximately 40 years of experience in finance, investment management, and investment banking. Prior to joining Inmagene, he was a Partner at Frazier Life Sciences, an investment management firm with approximately $5B under management. He was also the CFO and a board director of Frazier Life Sciences Acquisition Corporation which completed a highly successful merger with New Amsterdam Pharma in which David played a pivotal role. Prior, David was a Partner at General Atlantic Partners, a growth equity investment firm with approximately $35B under management. Prior, David was Co-Head of Equity Capital Markets at J.P. Morgan where he also served as Chairman of the Commitments Committee. Prior, David spent 22 years at Morgan Stanley where he served as Co-Head of Equity Capital Markets, Managing Director and Chairman of the Commitments Committee. David has also served on the boards of many companies, the Duke University Trinity School of Arts and Sciences, The Jewish Museum of New York and the Adams Memorial Foundation. David received his B.A. from Duke University and M.B.A. from Stanford University. Jonathan Wang, Ph.D., Chief Executive Officer of Inmagene said, "We are delighted to welcome David, an industry heavy weight, to join Inmagene. His deep knowledge in finance, investment management, and capital markets, as well as his strong experience in the biotech industry, will provide important contributions to our company's growth and strategy." David Topper, Chief Financial Officer of Inmagene said "I'm very excited to be joining Inmagene. I believe the company's multiple clinical stage assets and promising data, their focus on immunology and inflammation and the exceptional management team and shareholder base combine to make this a very exciting opportunity. I look forward to helping the company pursue its financial and capital markets objectives.." About Inmagene Inmagene is a global clinical-stage biotechnology company focused on developing novel therapeutics for immunological and inflammatory diseases. It has four clinical-stage drug candidates. The lead compound, IMG-007, an OX40 antagonist mAb with an extended half-life and a silenced ADCC function, is in two global POC clinical trials. IMG-004, a non-covalent, reversible Bruton's tyrosine kinase (BTK) inhibitor, which has demonstrated more durable pharmacodynamic effect and longer half-life than most, if not all, leading BTK inhibitors, is completing Phase 1 clinical development. IMG-008, a long-acting mAb against IL-36R with an extended half-life and enhanced antibody exposure compared to an approved IL-36R antagonist, is entering global Phase 1 clinical development. Moreover, IMG-020 (izokibep), an anti-IL-17 small protein therapeutic, is in global clinical development for 5 indications, including 2 pivotal trials, in collaboration with global partners. Based on its proprietary QuadraTek® platform, Inmagene discovers and develops novel drug candidates. Inmagene also sources innovation via in-licensing activities and, together with its partners, carries out global development activities. Inmagene has formed strategic partnerships with multiple partners, such as HUTCHMED and Affibody AB, to develop highly innovative drug candidates. Contact: Anna Vardanyan Vice President of Business Development vardanyana@inmagenebio.com SOURCE Inmagene

COLUMBUS, Ohio, Sept. 05, 2023 (GLOBE NEWSWIRE) -- Sermonix Pharmaceuticals LLC, a privately held biopharmaceutical company developing innovative therapeutics to specifically treat metastatic breast cancers harboring ESR1 mutations, today announced it shared an encore poster presentation at the 10th annual Metastatic Breast Cancer Research Conference (MBCRC) highlighting the results of its Phase 2 ELAINE-2 clinical study. The poster, “Lasofoxifene plus abemaciclib for treating ER+/HER2-, ESR1-mutated, metastatic breast cancer after progression on prior therapies: ELAINE-2 update,” was presented Wednesday, Aug. 30. “Sermonix welcomed the opportunity to share these important ELAINE-2 findings with researchers at MBCRC, who are highly focused experts in the metastatic breast cancer arena, in addition to the patient advocates who play such a vital role,” said Dr. David Portman, Sermonix founder and chief executive officer. “We also were pleased to discuss our plans for ELAINE-3, a registrational Phase 3 trial that if positive could bring lasofoxifene closer to becoming available as a potential new option to improve the lives of those confronted with this terrible disease.” ELAINE-2 (NCT04432454), an open-label Evaluation of Lasofoxifene in ESR1 Mutations (ELAINE) study of Sermonix’s lead investigational drug, lasofoxifene, in combination with Eli Lilly and Company’s CDK4/6 inhibitor abemaciclib, evaluated 29 heavily pre-treated women with ER+/HER2- locally advanced or metastatic breast cancer and an ESR1 mutation. Results were initially shared at the 2022 American Society of Clinical Oncology (ASCO) Annual Meeting and updated in June at ASCO 2023. The primary endpoint was safety/tolerability, with secondary endpoints including progression-free survival (PFS) and overall response rate (ORR). With patient follow-up through Jan. 31, 2023, the combination of lasofoxifene and abemaciclib continued to be well-tolerated, with clinically meaningful efficacy in women with ER+/HER2- metastatic breast cancer and an ESR1 mutation. The PFS, a median of 13 months, and ORR of 56% were promising. The results led Sermonix to initiate ELAINE-3, a global registrational study of 400 patients assessing the efficacy of lasofoxifene and abemaciclib compared to fulvestrant and abemaciclib, with enrollment planned to begin in the second half of 2023. To learn more about Sermonix Pharmaceuticals and lasofoxifene, visit . To learn more about the ELAINE studies, visit . About Lasofoxifene Lasofoxifene is an investigational novel endocrine therapy in clinical development which has demonstrated robust target engagement as an ESR1 antagonist in the breast, particularly in the presence of ESR1 mutations. Lasofoxifene has demonstrated anti-tumor activity as monotherapy and in combination with a CDK4/6 inhibitor in Phase 2 studies and has unique tissue selectivity distinguishing it from other current and investigational endocrine therapies, with beneficial effects seen on vagina and bone in previous clinical studies. Lasofoxifene, which Sermonix licensed globally from Ligand Pharmaceuticals Inc. (NASDAQ:LGND), has been studied in previous comprehensive Phase 1-3 non-oncology clinical trials in more than 15,000 postmenopausal women worldwide. Lasofoxifene’s bioavailability and activity in mutations of the estrogen receptor could potentially hold promise for patients who have acquired endocrine resistance due to ESR1 mutations, a common finding in the metastatic setting and an area of high unmet medical need. Lasofoxifene’s novel activity in ESR1 mutations was discovered at Duke University and Sermonix has exclusive rights to develop and commercialize the product in this area. Lasofoxifene, a novel targeted and tissue selective oral endocrine therapy could, if approved, play a critical role in the precision medicine treatment of advanced ER+ breast cancer. About Sermonix Sermonix Pharmaceuticals Inc. is a privately held biopharmaceutical company focused on the development of female-specific oncology products and is currently undertaking two Phase 2 clinical studies of lasofoxifene, its lead investigational drug. The Sermonix management team, led by founder Dr. David Portman, has significant experience in all stages of the drug development, regulatory and commercialization processes. Paul Plourde, M.D., vice president of oncology clinical development, has many decades of experience at AstraZeneca in the breast cancer drug development arena. Barry Komm, Ph.D., chief scientific officer, is recognized for his expertise in nuclear receptor biology. Miriam Portman, M.D., is co-founder and chief operating officer, with expertise in clinical trial conduct and patient recruitment. Elizabeth Attias, M.M.Sc., Sc.D., chief strategy and development officer, has extensive experience in pharmaceutical drug commercialization. Simon Jenkins, Ph.D., vice president of operations, has over 30 years of experience in global drug development leadership. Sermonix non-executive chairman of the board is Anthony Wild, Ph.D., former president of both Parke-Davis Pharmaceuticals and Warner-Lambert’s Pharmaceutical Division. Learn more at SermonixPharma.com. Sermonix Contact: Monica Kozlowski, MSPH Sermonix Product Manager mkozlowski@sermonixpharma.com 860-692-8548